[A22-27] Daratumumab (multiple myeloma) - Addendum to Commission A21-126
Last updated 18.03.2022
Project no.:
A22-27
Commission:
Commission awarded on 08.02.2022 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Adult patients with newly diagnosed multiple myeloma who cannot have autologous stem cell transplant
Result of dossier assessment:
Unchanged after addendum:
Hint of considerable added benefit
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-126 | Daratumumab (newly diagnosed multiple myeloma, unsuitable for stem cell transplantation) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
Federal Joint Committee (G-BA)
2022-03-18 A G-BA decision was published.